Accueil   Calls for projects   H2020 Nanotechnologies, Advanced Materials, Biotechnology and Advanced Manufacturing and Processing

H2020 Nanotechnologies, Advanced Materials, Biotechnology and Advanced Manufacturing and Processing

Key features of the call for projects

Porteur(s) de projet : Académique, Clinique, ETI, Grand groupe, PME

Opening date: October 31th, 2017

Date de clôture : January 23th, 2018

Dimension : Europe

Funding:

Type de financement : Subvention

Thématique(s) médicale(s) : Micro and nano technologies

Secteur(s) industriel(s) : Dispositifs médicaux et technologies médicales

The following topics focused on medical technologies, for the full list of calls under NMBP, please consult the work programme.

 

Answers to the calls below have to be submitted in two stages with the following deadlines:

 

  • 23 Jan 2018 (First Stage)
  • 28 Jun 2018 (Second Stage)

 

Call - FOUNDATIONS FOR TOMORROW'S INDUSTRY

DT-NMBP-02-2018: Open Innovation Test Beds for Safety Testing of Medical Technologies for Health (IA)

Open Innovation Test Beds should upgrade or develop materials facilities and make available to industry and interested parties, including SMEs, services for the design, development, testing, safety assessment, and upscaling of new/existing medical devices in compliance with EU regulatory frameworks since the beginning of the development process;   Test Beds could also contribute to develop methodologies to accelerate and simplify the subsequent pre-clinical and clinical testing in accordance with EU rules;   Potential regulatory, economic, organisational and technical barriers should be identified and assessed. Where applicable, considerations regarding risk-assessment procedures that take into account potential gender differences should be considered;   Open access at fair conditions and cost as well as outreach and dissemination across Europe, based on a distinct methodology;   Quality control processes and tools should be validated to allow on-line quality controls;  Medical devices should be demonstrated in relevant industrial environments.

Link to the participant portal

NMBP-13-2018: Risk Governance of nanotechnology (RIA)

Data and information management and framework tools with regard to the safety of nanomaterials for risk assessment, hazard and exposure, human health and environment, and risk mitigation including regulatory aspects of safe-by-design; Responsible communication with stakeholders and the civil society based on good quality information and valuable feedback; Plans for future scientific and regulatory research paying attention to social, ethical and environmental aspects, to achieve completeness, consistency, maximum synergy of actions and international cooperation; Mechanisms to monitor progress in several industrial sectors and to revise plans.

Link to the participant portal

NMBP-14-2018: Nanoinformatics: from materials models to predictive toxicology and ecotoxicology (RIA)

Development of models that support the prediction of both specific functionalities and hazard and are crucial to establish safe-by-design principles at early stages of material development;   Development of a sustainable multi-scale modelling framework, based on the integration/linking of different types of nanoinformatics models in order to advance towards predictively linking of physico-chemical NM property models to NM functionality and hazard;     Uptake and valid use of these tools and nanoinformatics models, user-friendly interfaces to enhance accessibility and usability of the nanoinformatics models, and clear explanations of their applicability domains, especially regulatory compliance, should be provided for different stakeholders (industry, regulators, and civil society).

Link to the participant portal

Call - TRANSFORMING EUROPEAN INDUSTRY

NMBP-22-2018: Osteoarticular tissues regeneration (RIA)

To design and develop user-centred innovative and smart nanobiomaterials which may be also adaptable to remote control, that will lead to a personalised regeneration of osteoarticular tissues (bones, cartilages, tendons, joints). The nanobiomaterials should be designed to perform in host tissues affected by severe degenerative and/or inflammatory processes, which typically characterise Osteoarticular pathologies. Proposals should cover at least one of the following technologies, leading to a convergence of processes:   (i) 3D-bioprinting; (ii) stem cells seeding, recruiting, activation, functionalisation, and cell printing; (iii) nano functionalisation; (iv) 3D-printable biophoto-polymerisation; (v) use of light to expose/mask tethered signalling molecules, incorporating immune-modulatory materials such as complement regulators; (vi) additive manufacturing by laser sintering, rapid prototyping technologies, stereolithography, inkjet techniques; (vii) relevant cross-cutting KETs; (viii) electrospinning.

Link to the participant portal

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree